The results showed that TUCAR-T cells exhibited comparable cellular efficacy in killing CD19+ Nalm6-Luc-GFP tumor cells to unedited CAR-T cells ex vivo (Figure 2A). The gene discussed is CD19; the disease is neoplasm.